Room-Temperature Palladium-Catalyzed CH Activation:<i>ortho</i>-Carbonylation of Aniline Derivatives
作者:Chris E. Houlden、Marc Hutchby、Chris D. Bailey、J. Gair Ford、Simon N. G. Tyler、Michel R. Gagné、Guy C. Lloyd-Jones、Kevin I. Booker-Milburn
DOI:10.1002/anie.200805842
日期:2009.2.23
Pd and CO—ureally got me! The title reaction proceeds efficiently at 18 °C under CO (1 atm) with 5 % [Pd(OTs)2(MeCN)2] as precatalyst. Depending on the solvents used, either anthranilates or cyclic imides can be obtained in high yields (see picture, BQ=benzoquinone, Ts=4‐toluenesulfonyl).
Pd 和 CO - 真的抓住了我!标题反应在 18 °C 下在 CO (1 atm) 下有效进行,使用 5% [Pd(OTs) 2 (MeCN) 2 ] 作为预催化剂。根据所使用的溶剂,可以高产率获得邻氨基苯甲酸酯或环状酰亚胺(见图,BQ=苯醌,Ts=4-甲苯磺酰基)。
One-pot synthesis of 2,3-difunctionalized indoles via Rh(<scp>iii</scp>)-catalyzed carbenoid insertion C–H activation/cyclization
作者:Honggui Lv、Jingjing Shi、Bo Wu、Yujuan Guo、Junjun Huang、Wei Yi
DOI:10.1039/c7ob01977g
日期:——
Reported herein is the first Rh(III)-catalyzedcarbenoidinsertionC–H activation/cyclization of N-arylureas and α-diazo β-keto esters. The redox-neutral reaction has the following features: good to excellent yields, broad substrate/functional group tolerance, exclusive regioselectivity, and no need for additional oxidants or additives, which render this methodology as a more efficient and versatile
Rhodium(<scp>iii</scp>)-catalyzed and MeOH-involved regioselective mono-alkenylation of N-arylureas with acrylates
作者:Honggui Lv、Jingjing Shi、Junjun Huang、Chao Zhang、Wei Yi
DOI:10.1039/c7ob01627a
日期:——
mono-alkenylation of arenes with acrylates using NHCONMe2 as the transformable directing group, giving direct access to diverse ortho-acrylated N-phenyl carbamates. The syntheticapplication of the obtained products to build privileged quinolin-2(1H)-ones and 3-(2-aminophenyl)acrylates has also been demonstrated in subsequent derivatization reactions.
TYROSINE KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
申请人:GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD
公开号:EP3293177A1
公开(公告)日:2018-03-14
The present invention relates to a tyrosine kinase inhibitor and a pharmaceutical composition comprising same. The tyrosine kinase inhibitor of the present invention has the structures as shown in the following formula (I) or (II):